Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — 9M 2021 Earnings Presentation
41 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2021
Slide 1: 9M2021 Results Update
9M2021 Results Update
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: List of Figures
List of Figures Corporate Overview 04 Near Term and Long Term Strategy 18 Breakdown by Customer Segment 33 Company Highlight 05 Network Expansion Plan 19 COVID-19 Test Breakdown 34 Company History 06 Leader in Next Gen Technology 20 Financial Update 35 Market Overview 07 Business Update 21 EBITDA 36
Slide 4: Corporate Overview
Corporate Overview 1
Slide 5: Company Highlight
IDR 1.99 Trillion • Established in 1973 with strong track record for more than 48 years experiences in 9M2021 Revenue (+65.6% yoy) Clinical Lab Industry • Pioneer and the leading clinical laboratory >2.6 Million testing Company with the most recognized Brand in Indonesia Patient Visits in 9M2021 (+3
Slide 6: Strong Track Record in Clinical Laboratory Testing
Strong Track Record in Clinical Laboratory Testing Received SMK3 accreditation and OHSAS The first private lab in Indonesia that Established professional Established 2015, along with the Award using fully automated Cobas 6800 for management team Prodia ChildLab as "Diagnostic Services RT-PCR
Slide 7: Market Overview
Market Overview 2
Slide 8: Indonesia Economic Outlook
Indonesia Economic Outlook 3.2% – 4.5% Indonesia’s GDP Growth Projection for 2021 Indonesia’s economic recovery and improvement in 2021 GDP Growth Projection 2021 will be supported by the Indonesia World effectiveness of Indonesia‟s Govt‟ 3.7% - 4.5% N/A COVID-19 pandemic World Bank 4.4% 5.6% contai
Slide 9: Investment Highlight
Investment Highlight 3
Slide 10: Largest Network & Market Share in Independent Clinical Lab Industry
Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2019 & 2020) (Billion IDR) 3YRS CAGR 7.4% 39.2% 39.5% 4,874 3YRS CAGR 4,551 4,222 8.2% 26.9% 2019 27.8% 2020 1,600 1,744 1,873 33.9% 32.7% 2018 2019
Slide 11: Strong Operational Track Record
Strong Operational Track Record VISITS REVENUE CAGR CAGR 5.4% 8.4% Prodia has generated continuous revenue growth 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 and increasing number of visits that supported REVENUE PER VISIT Company’s profitability EBITDA CAGR 2.8% CAGR 21.5% 2016 2017 2018 2019
Slide 12: Comprehensive Service Offering with Multiple Customer Segments
Comprehensive Service Offering with Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics One-stop shop, offering the most Esoteric Testing Referral Lab Services Doctor Consultation comprehensive Predictive, Preventive, General Medical Preventive Treatment range of clin
Slide 13: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved “Hub and spoke” model Centralized information Prodia Clinical Labs, offers scalable platform Prodia Referral with integrated IT Hospitals and Other Clinics platform tha
Slide 14: Strong Relationship with Medical Community
Strong Relationship with Medical Community Strong relationships through the work of more Introduced new tests, such as NIPT ProSafe, Amino Acid Profile, than 500 Marketing and Laboratory Fatty Acid Profile, CArisk, DIArisk, Liquid biopsy EGFR Mutation, New Information Service personnel Born Screenin
Slide 15: Experienced Senior Leadership and Management Team
Experienced Senior Leadership and Management Team Professional Management Team with Strong Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 48 Experience 48 Experience 38 Experience 30 Experience 30 Experience Andi Gunawan Endang Kemal Imam Keri
Slide 16: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% Contract Research, therapy Distributor for Research and banking of healthcare Organization stem cell products PT Prodia Widyahusada Tbk Occupational In Vitro Health Diagnostics Nationwide Outlet Network across Indonesia
Slide 17: Growth Strategy
Growth Strategy 4
Slide 18: Growth Strategy
Growth Strategy Strengthen digital capabilities to Expand our presence and enable business growth grow our network of outlets in both physical and digital Develop data & analytics channel in Indonesia Near- capabilities to create business values A term Upgrade existing clinical Enhance internal oper
Slide 19: Prodia's Network Expansion Plan 2016 - 2021
Prodia’s Network Expansion Plan 2016 - 2021 1 2 3 4 5 Expand Network Upgrade Enhance Focus on Digital Service of Outlets Clinical Labs Operating Quality Development 31 regional referral labs Upgrade up to 39 Efficiency Mobile apps and clinical labs to PHC3 Clinics other digital services Up to 33 add
Slide 20: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me
Slide 21: Business Update
Business Update 5
Slide 22: Response to COVID-19 Pandemic
Response to COVID-19 Pandemic Develop COVID-19 Related Test: RT-PCR, Antibody, Antigen testing Expand More Collaboration and Partnership: More Hospital Referral especially for COVID-19 test and for Swab Sampling Create New Ways of Service: Cleanliness, Safety, Convenience Revisit Budget and Strategy
Slide 23: Deliver Solution for Customer Needs
DELIVER SOLUTION FOR CUSTOMER NEEDS Respond to People Behavior Changing and Customer‟s Voice Services & Lab Online Marketing Product Lab Testing in Facilities and Education Innovation COVID-19 Pandemic Activities • Prodia Mobile • Digital • Complete Testing from • COVID-19 Testing • Home/Office Serv
Slide 24: Digital Transformation to Fulfill Customer Needs
Digital Transformation to Fulfill Customer Needs > > Prodia has enhanced its digital platform services New Prodia Mobile Ver. 3 – Launched in Jan 2021 24
Slide 25: Digital Apps 9M2021 Highlights
Digital Apps 9M2021 Highlights Prodia Mobile 309.1% number of downloaders growth vs. 9M2020 570.2% orders growth vs. 9M2020 Place your screenshot here 602.5% revenue growth vs. 9M2020 Digital Collaboration 25
Slide 26: Home Service Highlights
Home Service Highlights 9M20-9M21 growth +269.2% Contribution to 100.0 5.0% Total Revenue 80.0 4.0% 4.3% 60.0 3.0% Revenue 40.0 2.0% 20.0 1.9% 1.0% 1.3% - 0.0% 9M2019 9M2020 9M2021 9M20-9M21 Contribution to Total growth +161.4% 85,000 3.0% Visit 2.8% 2.5% 65,000 2.0% 45,000 1.5% Visit 1.5% 1.0% 25,0
Slide 27: New Innovation & Enhancement
Customer Centric Model New Innovation & Enhancement Prodia in your Car Service Prodia Home Customer Service Centric Tele-Consultation Tele-Radiology • General Practitioners • Clinical Pathologists Tele-Health* • Internist • Clinical Nutritionist • Sport Medicine 27
Slide 28: Outlet Development
Outlet Development 2021 Outlet 2016-2021 Outlet Development Development Target 259 292 287 267 257 1-2 20 283 Clinical Labs POC Outlets 5 7 4** 4** 2 4** 11 14 14 12 9 10 Total Outlet 130 128 122 103 95 1-2 1 118 Specialty Clinics Hospital Lab Hospital Labs Specialty Clinic 129 136 143 147* 148* 148
Slide 29: 9 New Tests Launched in 9M2021
Predictive, Preventive & Screening Targeted Diagnostic Pharmacogenomics Therapy 1. NIPT (ProSafe) 26. ADMA/SDMA 35. Jak2 Mutation 51. Jak 2 Mutation 61. Warfarin Indiv Test 2. Telomere Analysis 27. Prodia Skin and 36. Kidney Stone Analysis (FTIR) 52. Mutation EGFR (CYP2C9 & VCORC1 3. Vitamin A & E H
Slide 30: 9M2021 Revenue
9M2021 Revenue Quarterly Revenue Revenue (Unaudited) (Unaudited) in IDR Billion in IDR Billion FY16-FY20 CAGR +8.4% 9M17-9M21 CAGR +17.6% 2021 2020 2019 2018 2017 2016 • Revenue grew 9M20-9M21 3Q21, sharply by +65.6% in growth: +65.6% 752.3 9M21 yoy, mostly 1,990.7 1Q21, driven by walk in and 1,873.
Slide 31: 9M2021 Number of Visit and Revenue per Visit
9M2021 Number of Visit and Revenue per Visit Number of Visits (in „000) Revenue per Visit (in IDR „000) FY16-FY20 CAGR +5.4% 9M17-9M21 CAGR +10.6% FY16-FY20 CAGR +2.8% 9M17-9M21 CAGR +6.3% 1H20-1H21 9M20-9M21 growth +37.6% growth +20.3% 3,061 2,482 2,503 2,482 2,571 2,684 742 1,790 1,748 1,850 1,950
Slide 32: 9M2021 Test Volume & Test per Visit
9M2021 Test Volume & Test per Visit Test Volume (in „000) Test per Visit FY16-FY20 CAGR -1.0% 9M17-9M21 CAGR +7.2% FY16-FY20 CAGR -6.1% 9M17-9M21 CAGR -3.1% 9M20-9M21 9M20-9M21 growth +7.6% growth +48.0% 15,958 16,520 6.43 6.42 14,59115,129 13,999 13,726 5.88 6.05 6.22 6.20 5.80 11,462 5.11 10,388 1
Slide 33: 9M2021 Customer Segments and Testing Types
9M2021 Customer Segments and Testing Types Diversified Walk-in Customers Doctor Referrals • Individual walk-in patients • Patients referred by doctors Customer Base 35.6% • Out-of-pocket cash • Out-of-pocket cash 32.8% 9M2021 payment payment Revenue Split External Referral Corporate clients • Primar
Slide 34: 9M2021 COVID-19 Test Breakdown
9M2021 COVID-19 Test Breakdown Revenue Contribution SARS-CoV-2 RNA COVID-19 Tests by Customer Segment 0.7% (PCR COVID-19) Revenue 12.8% 2.7% Anti SARS-CoV-2 2.3% (Rapid/Serology) Corporate SARS-CoV-2 Ag Clients, Walk in, 0.6% (Antigen) 21.9% 29.7% Anti SARS-CoV-2 Quantitative External 80.9% GP COVID
Slide 35: Financial Update
Financial Update 6
Slide 36: 9M2021 EBITDA (Unaudited)
9M2021 EBITDA (Unaudited) EBITDA (in IDR Billion) FY16-FY20 CAGR +21.5% 9M17-9M21 CAGR +47.9% 9M20-9M21 EBITDA Margin growth: +218.4% 800.0 745.0 65.0% EBITDA significantly 700.0 improves due to cost 600.0 55.0% 455.0 . efficiency, revenue 500.0 45.0% recovery, and impact 400.0 316.0 35.0% 239.1 277
Slide 37: 9M2021 Gross Profit & Net Income (Unaudited)
9M2021 Gross Profit & Net Income (Unaudited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) FY17-FY20 CAGR +7.0% 9M17-9M21 CAGR +19.6% FY17-FY20 CAGR +21.2% 9M17-9M21 CAGR +50.8% 9M20-9M21 9M20-1H9M21 growth +88.4% growth +318.0% 1,232.9 511.1 1,041.0 1,046.2 942.8 853.5 602.2 646.0 722.3
Slide 38: 9M2021 COGS & OPEX (Unaudited)
9M2021 COGS & OPEX (Unaudited) COGS (in IDR Billion) OPEX (in IDR Billion) FY16-FY20 CAGR+10.0% 9M17-9M21 CAGR+14.6% FY16-FY20 CAGR +3.3% 9M17-9M21 CAGR +3.9% 9M20-9M21 0 growth +38.4% 1,000 827 827 9M20-9M21 758 80.0% 770 746 growth +14.3% 100.0% 0 703 800 676 713 50 657 46 565 612 125 104 70.0% 41
Slide 39: CAPEX Spending and Dividend Payout
CAPEX Spending and Dividend Payout CAPEX Spending (IDR Billion) Dividend Payout (IDR Billion) Payout Ratio 208 161.25 168 141 143 60% 81 105.13 87.73 50% 60.32 50% 2017 2018 2019 2020 9M2021 40% 26.44 30% CAPEX Plan for 2021: IDR 200-300 Billion Building: 40-45% Rent & Renovation: 5-10% 2016 2017 20
Slide 40: 9M2021 Financial Summary (Unaudited)
9M2021 Financial Summary (Unaudited) (in IDR Bn) 9M2021 9M2020 Change (in IDR Bn) 9M2021 9M2020 Change Revenue 1,990.7 1,202.1 +65.6% Total Asset 2,611.9 2,069.9 +26.2% Gross Profit 1,232.9 654.5 +88.4% Gross Profit Margin 61.9% 54.5% +740bps Total Equity 2,140.9 1,668.3 +28.3% EBIT 626.1 122.3 +412
Slide 41: Thank You!
Thank You! For more information : PT Prodia Widyahusada Tbk investor.relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150, Jakarta 10430, Indonesia Phone +6221-3144182 ext. 3774, 3775 www.prodia.co.id 41
PT Prodia Widyahusada — 9M 2021 Earnings Presentation on 6ix